Dr G G Forstner, Division of Gastroenterology and Nutrition, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada email:gforst{at}sickkids.on.ca BACKGROUND AND AIMS ...

1 Internal Medicine, Gastroenterology and Liver Unit, “Agostino Gemelli” University Hospital, Catholic University of Rome, Italy The recent increase in our knowledge of human gut microbiota has ...

Objective Antireflux surgery can be proposed in patients with GORD, especially when proton pump inhibitor (PPI) use leads to incomplete symptom improvement. However, to date, international consensus ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

8 Beijing Institute of Hepatology, Beijing You’an Hospital, Capital Medical University, Beijing, People's Republic of China Conclusion Our findings underscore the hepatoprotective effect of ECM1, ...

Correspondence to Professor Nigel W Bunnett, Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; nwb2{at}nyu.edu Objective The effectiveness of ...

Background and aims Quantifying systemic inflammation (SI) in acutely decompensated cirrhosis (ADC) is of major importance ...

The treatment of long benign oesophageal strictures remains a clinical challenge. We present a novel endoscopic technique that involves visualising scar tissue using methylene blue-stained saline, ...

We thank Dr Yang and colleagues for their interest in the HELIOS trial and their thoughtful appraisal of our findings.1 2 Yang et al highlight the possibility that heterogeneity in endoscopist ...

4 Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches; Centre for Research in Epidemiology and Population Health (CESP), Team MOODS, Inserm UMRS 1018, ...

Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such ...